Rarity of EGFR and c-erbb-2 Overexpressions in Hepatocellular Carcinoma: An Immunohistochemical Study
|
|
- Jesse Powers
- 5 years ago
- Views:
Transcription
1 The Korean Journal of Pathology 2004; 38: Rarity of EGFR and c-erbb-2 Overexpressions in Hepatocellular Carcinoma: An Immunohistochemical Study Woo Sung Moon Hyun Jin Son Ho Sung Park Min Young Park Department of Pathology, Chonbuk National University, Medical School and Institute for Medical Sciences, Jeonju, Korea Received : May 31, 2004 Accepted : July 29, 2004 Corresponding Author Woo Sung Moon, M.D. Department of Pathology, Chonbuk National University, Medical School, San 2-20 Keumam-dong, Duckjin-gu, Jeonju , Korea Tel: Fax: mws@chonbuk.ac.kr *This paper was supported by research funds of Chonbuk National University. Background : The overexpression of epidermal growth factor receptor (EGFR) and c-erbb- 2 oncogenes has been implicated in the development of many types of cancer. However, the role of EGFR and c-erbb-2 overexpression in hepatocellular carcinoma (HCC) has not been fully elucidated. Methods : The aim of this study was to evaluate the immunohistochemical expression of EGFR and c-erbb-2 oncoprotein in a series of 52 HCCs. Results : All but one of the HCC tumor tissues were negative for EGFR monoclonal antibody, clone H11. All of the HCC tumor tissue samples were negative for EGFR monoclonal antibody, clone However, strong EGFR immunoreactivity was detected in sinusoidal endothelial cells of HCC in 25 tumors (48%) using EGFR antibody. The expression of c-erbb-2 was observed in 6% (3/52) of the HCCs. No significant correlation was found between p53 mutation and the expression of c-erbb-2. Conclusion : Our results suggest that both EGFR and c-erbb-2 oncoprotein overexpressions in tumor cells are rare and do not seem to predominantly contribute to the malignant phenotype in HCC. Key Words : Carcinoma, Hepatocellular-Receptor, Epidermal Growth Factor-erbB-2- Immunohistochemistry The epidermal growth factor receptor (EGFR) family includes four homologous transmembrane receptor protein kinases: EGFR, c-erbb-2, c-erbb-3, and c-erbb-4. This receptor family plays a crucial role for regulating cell proliferation, differentiation and transformation, and particularly for the transmission of growth signal transduction in cells. Ligand-induced activation of these receptors results in formation of homo- and heterodimers that undergo transphosphorylation and transactivation. 1-3 The overexpression of EGFR and c-erbb-2 has been found in a variety of human malignancies and their role in the development and progression of cancer has been described. 2,4-6 Accumulating evidences have demonstrated that anti-egfr or anti-c-erbb-2 therapies are effective in several types of cancer However, the role of EGFR and c-erbb-2 overexpression in hepatocellular carcinoma (HCC) is still controversial Several studies have also demonstrated an increased expression of EGFR and c-erbb-2 in human HCC. 11,14,15 On the other hand, other studies have demonstrated a lack of correlation between HCC development and EGFR or c-erbb-2 overexpression. 12,13 Wild-type p53 is a tumor suppressor gene product that blocks progression of cells through the cell cycle. 16 It has been shown that p53 can either activate or suppress the activity of a number of target genes. Wild-type p53 contributes to growth inhibition by regulating, directly or indirectly, the expression of genes that are required for ongoing proliferation. 17 A mutation in the p53 gene often results in a prolonged half-life of the protein compared to wild type, and the loss of normal functions. 18 Therefore, positive nuclear staining suggests mutated or overexpressed p53. These findings stimulated our study to investigate the expression and cellular localization of EGFR and c-erbb-2 by using immunohistochemistry in resected human HCC specimens. In addition, we examined the relationship between overexpression of p53 by using immunohistochemisty, and the expression of EGFR and c-erbb-2 in HCC. 244
2 EGFR, c-erbb-2 in HCC 245 MATERIALS AND METHODS Patients and specimens The Human Ethics Committee of Chonbuk National University Medical School approved this study. We retrospectively studied the HCC specimens obtained from 52 patients who were treated between 1990 and 1999 at the Chonbuk National University Hospital. All patients underwent surgical resection of their tumors. Of the 52 patients with HCC, 40 were men and 12 were women, and the mean age of the patients was 54 years (range, years). HBV and HCV serologies were positive in 31 and 5 patients, respectively. The non-tumorous liver tissue was composed of 25 cirrhotic specimens and 9 chronic hepatitis specimens. Immunohistochemistry For the p53 immunohistochemical staining, the immunoperoxidase method was used with the Streptoavidin-biotinylated horseradish peroxidase complex (DAKO, Carpinteria, CA, USA). Sections 4 m thick were cut from the formalin-fixed paraffinembedded tissue blocks. After deparaffinization, they were incubated in methanol containing 0.3% hydrogen peroxide at room temperature for 20 min to block endogenous peroxidase, and then they were treated with a microwave antigen retrieval procedure in 0.01 M sodium citrate buffer for 10 min. After blocking the endogenous biotin, the sections were incubated with Protein Block Serum-Free (DAKO, Carpinteria, CA, USA) at room temperature for 10 min to block nonspecific staining and then incubated for 2 h at room temperature with anti-p53 antibody (DAKO, Carpinteria, CA, USA). After washing, the sections were incubated with a biotin-conjugated secondary antibody at room temperature for 30 min, and they were finally incubated with peroxidase conjugated streptoavidin at room temperature for 30 min. Peroxidase activity was detected with the enzyme substrate 3-amino-9-ethyl carbazole. For EGFR and c-erbb2 staining, the DAKO Envision system, employing dextran polymers conjugated with alkaline phosphatase, was used to avoid endogenous biotin contamination. After deparaffinization, the slides were treated with the microwave antigen retrieval procedure or proteinase K treatment for EGFR, Clone H11 (a monoclonal antibody obtained by a combined immunization with the microsomal membrane of HC2 20 d2 xenograft cells and a 14 amino acid EGFRvIII-specific synthetic peptide, DAKO, Carpinteria, CA), EGFR, Clone (a monoclonal antibody raised on human carcinoma cell line A431, Sigma, St. Louis, MO, USA) and c-erbb-2, (C-18, Santa Cruz Biotechnology, Santa Cruz, CA, USA) for 10 min was performed. After blocking the endogenous alkaline phosphatase, the sections were incubated for 2 h at room temperature with the above antibodies. Fast red solution was used for the localization of the antibodies. For the negative controls, the sections were treated the same way except they were incubated with Tris buffered saline instead of the primary antibody. Sections taken from known EGFR and c-erbb-2 positive cases of colon carcinoma were used as positive controls. Immunostaining was scored as follows: score 0, undetectable staining or membrane staining in <10% of the tumor cells; score 1+, weak membrane staining detected in >10% of the tumor cells; score 2+, weak to moderate complete membrane staining observed in >10% of the tumor cells; score 3+, strong complete membrane staining observed in >10% of the tumor cells. Samples with staining of at least 10% of the tumor cells were defined as a positive case. Stains for EGFR and c-erbb-2 protein were interpreted as positive only if membrane accentuation was obtained. Statistical analysis An association between the expression of c-erbb-2 and p53 protein overexpression was evaluated for by chi-square testing. A p value 0.05 was considered significant. RESULTS The results are summarized in Table 1. The EGFR was detected in 1 out of 52 cases of HCC using the monoclonal antibody Table 1. Immunoreactivity for EGFR and c-erbb-2 in hepatocellular carcinoma Name of antibodies Number of positive cases/ Number of total cases Tumor cell reactivity Non-tumorous elements stained EGFR, Clone H11 1/52 Diffuse, 2+, cytoplasmic with membrane accentuation EGFR, Clone /52 Sinusoidal endothelial cells of HCC (48%) and cirrhotic liver (16%) c-erbb-2 3/52 Diffuse, 2+, membranous
3 246 Woo Sung Moon Hyun Jin Son Ho Sung Park, et al. A B C D Fig. 1. (A) A case of well differentiated HCC showed cytoplasmic staining with membrane accentuation for EGFR (clone H11) protein. (B) Sinusoidal endothelial cells in HCC showed strong staining for EGFR (clone ) protein. (C) A case of poorly differentiated HCC showed membrane staining for c-erbb-2 protein. (D) Positive control for EGFR staining from a colon carcinoma tissue. H11 (Fig. 1A). All of the HCC tumor tissue samples were negative for EGFR, clone expression. However, strong EGFR immunoreactivity was detected in the sinusoidal endothelial cells of HCC in 25 (48%) tumors and in 4 cirrhotic liver specimens (16%) using monoclonal antibody (Fig. 1B). Only 3 cases of 52 (6%) HCC specimens showed positive staining for c-erbb- 2. The c-erbb-2 was diffusely expressed in the cytoplasmic membranes of positive tumor cells and less frequently, in their cytoplasm (Fig. 1C). Non-neoplastic hepatocytes and bile ducts adjacent to the tumor also were negative. All the positive and negative controls stained appropriately (Fig. 1D). P53 overexpression was observed in 17 of 52 tumors (33%), and the staining was nuclear in all positive cases. We could not find a significant correlation between c-erbb-2 expression and p53 overexpression (p=0.98).
4 EGFR, c-erbb-2 in HCC 247 DISCUSSION It has been reported that 47-68% 11,15 and % 12,14 of human HCC tissue samples overexpress the EGFR and c-erbb-2 protein as demonstrated by immunohistochemistry, respectively. Voravud et al. 14 have reported that the expression of c-erbb-2 was observed in 86% (12/14) of HCC using rabbit polyclonal anti-c-erbb-2 antibody (ICRF, Molecular Oncology Laboratory, Hammersmith Hospital). Nakopoulou et al. 12 have reported that the expression of c-erbb-2 was observed in 30% (21/71) of HCC using monoclonal antibody 3 B5 raised against a synthesis peptide at the C-terminal end of the c-erbb-2 gene product (Oncogene Science). The above studies suggested the possible role of EGFR and c- erbb-2 for the development or progression of human HCC. In contrast to the above results, the present study showed that all but one of the HCCs was negative for EGFR when using two different EGFR monoclonal antibodies. Only three cases out of 52 specimens of HCC overexpressed c-erbb-2. Our findings indicate that EGFR and c-erbb-2 overexpression is rare in HCC. Our results are in agreement with those results recently reported by others. 13,19,20 Prange and Schirmacher 19 have demonstrated the lack of c-erbb-2 overexpression in HCC. The other studies have reported only 2.8% (1/36) 13 and 7.7% (2/26) 20 of HCC overexpressed c-erbb-2 as evidenced by membrane staining. Moreover, c-erbb-2 mrna was not detected in the seven HCCs examined by Northern blot analysis. 20 Only one of the 12 HCC cell lines revealed a significant level of c-erbb-2 expression by Western blotting. 13 Similarly, Nakopoulou et al. 12 have reported that only 3 cases out of 71 cases of HCC showed heterogenous membrane expression of EGFR by using mouse monoclonal anti-egfr antibody (Biomaker). In our study, the presence of cell membrane staining was considered an essential criterion for the identification of EGFR or c-erbb-2 overexpression, and the dextran polymer method was used to avoid endogenous biotin contamination. The previous studies did not distinguish between cytoplasmic and membrane staining, or details of the scoring criteria used in their study were not provided. 12,14 The significance of cytoplasmic staining without membrane immunoreactivity for EGFR or c-erbb-2 remains unclear. However, previous studies have suggested that a membrane staining using immunohistochemistry more accurately reflected the expression of HER-2/neu oncoprotein on cell membrane in a breast biopsy specimen. 21 The membrane staining was never found in breast tumor specimens with a normal c-erbb-2 oncogene copy number. 22 The discrepancy of the incidence of overexpression of EGFR and c-erbb-2 may be due to the different criteria for positivity, and the different antibodies and detection methods used. Our results, along with those of the above authors, suggest that the significance of EGFR and c-erbb-2 expression in HCCs as a true oncogenic event must be considered with trepidation. This negative result occurring with the use of specific monoclonal antibodies in an established immunohistochemical method for the analysis of EGFR and c-erbb- 2 does not exclude the presence of these receptors in HCC, but it does suggest that if present, they occur in much smaller amounts than in colon or gastric cancer tissue. Our study showed strong EGFR immunoreactivity to monoclonal antibody in sinusoidal endothelial cells of HCC and those of regenerating nodules, but there was no immunoreactivity to monoclonal antibody H11. The reasons for the different expression patterns of EGFR when using different EGFR antibodies are unclear. The different antibodies used in this study, which detect different epitopes, may explain the apparent discrepancy in different localization of EGFR. Ross et al. 23 have shown that increased angiogenic growth factor receptors in endothelial cells such as VEGF receptor, angiopoietin receptors, platelet-derived growth factor receptor beta and epidermal growth factor receptor during the revasculization of regenerating rat liver. Strong immunoreactivity in vascular endothelial cells of meningioma has been reported using same monoclonal antibody for EGFR, and the researchers suggested that EGFR might participate in angiogenesis of meningioma. 24 When taken together, our results suggest that the EGFR expression in tumor endothelial cells may play a role in tumor angiogenesis in HCC. Additional investigations are necessary to determine the relationship between EGFR expression for tumor endothelium and angiogenesis. Finally, our current study did not demonstrate a statistically significant association between p53 overexpression and expression of c-erb-b2 in HCC tissue specimen. In conclusion, our results suggest that both EGFR and c-erbb- 2 overexpression do not seem to predominantly contribute to the malignant phenotype in HCC. REFERENCES 1. Prigent SA, Lemoine NR. Type 1 (EGFR-related) family of growth factor receptors and their ligands. Prog Growth Factor Res 1992; 4: Barnard JA, Beauchamp J, Rissell WE, Dubois R, Coffey R. Epidermal growth factor-related peptides and their relevance to gastrointestinal pathophysiology. Gastroenterology 1995; 108: Cantley LC, Auger KR, Carpenter C, et al. Oncogenes and signal trasduction. Cell 1991; 64:
5 248 Woo Sung Moon Hyun Jin Son Ho Sung Park, et al. 4. Ross JS, Fletcher JA. HER-2/neu (c-erbb2) gene and protein in breast cancer. Am J Clin Pathol 1999; 112(Suppl 1): S Rajkumar T, Stamp GWH, Pandha HS, Waxman J, Gullick WJ. Expression of the type I tyrosine kinase growth factor receptors: EGF receptor, c-erbb-2 and c-erbb-3 in bladder cancer. J Pathol 1996; 179: Lee EY, Cibull ML, Strodel WE, Haley JV. Expression of HER-2/neu oncoprotein and epidermal growth factor receptor and prognosis in gastric carcinoma. Arch Pathol Lab Med 1994; 118: Solbach C, Roller M, Ahr A, et al. Anti-epidermal growth factor receptor-antibody therapy for treatment of breast cancer. Int J Cancer 2002; 101: O dwyer PJ, Benson AB 3rd. Epidermal growth factor receptor-targeted therapy in colorectal cancer. Semin Oncol 2002; 29 (Suppl): Gianni L. The future of targeted therapy:combining novel agents. Oncology 2002; 63 (Suppl): Baselga J. Why the epidermal growth factor receptor? The rationale for cancer therapy. Oncologist 2002; 7 (Suppl): Ito Y, Takeda T, Sakon M, et al. Expression and clinical significance of erb-b receptor family in hepatocellular carcinoma. Br J Cancer 2001; 18: Nakopoulou L, Stefanaki K, Filaktopoulos D, Giannopoulou I. C-erb- B-2 oncoprotein and epidermal growth factor receptor in human hepatocellular carcinoma: an immunohistochemical study. Histol Histopathol 1994; 9: Hsu C, Huang CL, Hsu HC, Lee PH, Wang SJ, Cheng AL. HER-2/ neu overexpression is rare in hepatocellular and not predictive of anti-her-2/neu regulation of cell growth and chemosensitivity. Cancer 2002; 94: Voravud N, Foster CS, Gilbertson JA, Sikora K, Waxman J. Oncogenic expression in cholangiocarcinoma and in normal hepatic development. Hum Pathol 1989; 20: Kira S, Nakanishi T, Suemori S, Kitamoto M, Watanabe Y, Kajiyama G. Expression of transforming growth factor alpha and epidermal growth factor receptor in human hepatocellular carcinoma. Liver 1997; 17: Oren M. p53: the ultimate tumor suppressor gene? FASEB J. 1992; 6: Ginsberg D, Mechta F, Yaniv M, Oren M. Wild-type p53 can downmodulate the activity of various promoters. Proc Natl Acad Sci US A. 1991; 88: Zambetti GP, Levine AJ. A comparison of the biological activities of wild type and mutant p53. FASEB J. 1993; 7: Prange W, Schirmacher P. Absence of therapeutically relevant c-erbb- 2 expression in human hepatocellular carcinoma. Oncol Rep 2001; 8: Collier JD, Guo K, Mathew J, et al. C-erbB-2 oncogene expression in hepatocellular carcinoma and cholangiocarcinoma. J Hepatol 1992; 14: Watson C, Martin AW, Wiehle RD, Dauphinis RM, Wittliff JL. Interrelationship of results from immunohistochemical and biochemical determinations of HER-2/neu oncoprotein in breast cancer. Am J Clin Pathol 1991; 96: 405. (abstract) 22. van de Vijver MJ, Mooi WJ, Wisman P, Peterse JL, Nusse R. Immunohistochemical detection of the neu protein in tissue sections of human breast tumors with amplified neu DNA. Oncogene 1988; 2: Ross MA, Sander CM, Kleeb TB, Watkins SC, Stolz DB. Spatiotemporal expression of angiogenesis growth factor receptors during the revascularization of regenerating rat liver. Hepatology 2001; 34: Shiurba RA, Eng LF, Vogel H, Lee Y-L, Horoupian DS, Urich H. Epidermal growth factor receptor in meningiomas is expressed predominantly on endothelial cells. Cancer 1988; 62:
HER2 status assessment in breast cancer. Marc van de Vijver Academic Medical Centre (AMC), Amsterdam
HER2 status assessment in breast cancer Marc van de Vijver Academic Medical Centre (AMC), Amsterdam 13e Bossche Mamma Congres 17 th June 2015 Modern cancer therapies are based on sophisticated molecular
More informationPitfalls in the diagnosis of well-differentiated hepatocellular lesions
2013 Colorado Society of Pathology Pitfalls in the diagnosis of well-differentiated hepatocellular lesions Sanjay Kakar, MD University of California, San Francisco Outline Hepatocellular adenoma: new WHO
More informationSOMATOSTATIN RECEPTORS IN HEPATOCELLULAR CARCINOMA. Marie LEQUOY Saint-Antoine Hospital, Department of Hepatology, Paris, France
SOMATOSTATIN RECEPTORS IN HEPATOCELLULAR CARCINOMA Marie LEQUOY Saint-Antoine Hospital, Department of Hepatology, Paris, France Somatostatin : SST Somatostatin (SST) protein : 2 active forms (alternative
More informationEvaluation of cyclin-dependent kinase inhibitor p27 and Bcl-2 protein in nonsmall cell lung cancer
166 Turkish Journal of Cancer Volume 35, No.4, 2005 Evaluation of cyclin-dependent kinase inhibitor p27 and cl-2 protein in nonsmall cell lung cancer LEVENT DERTS Z 1, GÜLY ÖZ L M 2, LKNUR KÜKNER 2, REM
More informationHER2/neu Amplification in Breast Cancer Stratification by Tumor Type and Grade
Anatomic Pathology / HER2/NEU AMPLIFICATION IN BREAST CANCER HER2/neu Amplification in Breast Cancer Stratification by Tumor Type and Grade Elise R. Hoff, MD, Raymond R. Tubbs, DO, Jonathan L. Myles, MD,
More informationCell Culture. The human thyroid follicular carcinoma cell lines FTC-238, FTC-236 and FTC-
Supplemental material and methods Reagents. Hydralazine was purchased from Sigma-Aldrich. Cell Culture. The human thyroid follicular carcinoma cell lines FTC-238, FTC-236 and FTC- 133, human thyroid medullary
More informationCarcinoembryonic antigen (CEA)
Assessment Run 37 2013 Carcinoembryonic antigen (CEA) Material The slide to be stained for CEA comprised: 1. Appendix, 2. Liver, 3-4. Colon adenocarcinoma, 5. Urothelial carcinoma All tissues were fixed
More informationHigh expression of fibroblast activation protein is an adverse prognosticator in gastric cancer.
Biomedical Research 2017; 28 (18): 7779-7783 ISSN 0970-938X www.biomedres.info High expression of fibroblast activation protein is an adverse prognosticator in gastric cancer. Hu Song 1, Qi-yu Liu 2, Zhi-wei
More informationExpression of the GLUT1 and p53 Protein in Atypical Mucosal Lesions Obtained from Gastric Biopsy Specimens
The Korean Journal of Pathology 2006; 40: 32-8 Expression of the GLUT1 and p53 Protein in Atypical Mucosal Lesions Obtained from Gastric Biopsy Specimens In Gu Do Youn Wha Kim Yong-Koo Park Department
More informationCitation Acta Medica Nagasakiensia. 1992, 37
NAOSITE: Nagasaki University's Ac Title Author(s) A Study on the Expression of EGFR a Content in the Stomach Cancer Tissu Nakazaki Takayuki Citation Acta Medica Nagasakiensia. 1992 37 Issue Date 1992-12-25
More informationmicrorna Presented for: Presented by: Date:
microrna Presented for: Presented by: Date: 2 micrornas Non protein coding, endogenous RNAs of 21-22nt length Evolutionarily conserved Regulate gene expression by binding complementary regions at 3 regions
More informationAssessment Run CK19
Assessment Run 29 200 CK9 The slide to be stained for CK9 comprised:. Appendix, 2. Thyroid gland, 3. Pancreas, 4. Ductal breast carcinoma, 5. Esophagus, 6. Papillary thyroid carcinoma. All tissues were
More informationProduct Introduction
Product Introduction Product Codes: HCL026, HCL027 and HCL028 Contents Introduction to HER2 2 HER2 immunohistochemistry 3 Cell lines as controls 5 HER2 Analyte Control DR IHC 7 HER2 Analyte Control DR
More informationAssessment Run GATA3
Assessment Run 44 2015 GATA3 Material The slide to be stained for GATA3 comprised: 1. Tonsil 2. Kidney, 3. Urothelial carcinoma, 4. Breast ductal carcinoma, 5. Colon adenocarcinoma All tissues were fixed
More informationPhospho-AKT Sampler Kit
Phospho-AKT Sampler Kit E 0 5 1 0 0 3 Kits Includes Cat. Quantity Application Reactivity Source Akt (Ab-473) Antibody E021054-1 50μg/50μl IHC, WB Human, Mouse, Rat Rabbit Akt (Phospho-Ser473) Antibody
More informationSonic hedgehog expression in gastric cancer and gastric adenoma
ONCOLOGY REPORTS 17: 1051-1055, 2007 Sonic hedgehog expression in gastric cancer and gastric adenoma SUN-YOUNG LEE 1, HYE SEUNG HAN 2, KYUNG YUNG LEE 3, TAE SOOK HWANG 2, JEONG HWAN KIM 1, IN-KYUNG SUNG
More informationSingle and Multiplex Immunohistochemistry
Single and Multiplex Immunohistochemistry Steve Westra, BS Reagent Product Specialist Leica Biosystems IHC Theory Polyclonal vs Monoclonal Polyclonal reagents Detect a multitude of epitopes Batch to batch
More informationIMMUNOHISTOCHEMICAL EXPRESSION OF TISSUE INHIBITOR OF METALLOPROTEINASE-1 (TIMP-1) IN INVASIVE BREAST CARCINOMA
& IMMUNOHISTOCHEMICAL EXPRESSION OF TISSUE INHIBITOR OF METALLOPROTEINASE-1 (TIMP-1) IN INVASIVE BREAST CARCINOMA Suada Kuskunović*, Svjetlana Radović, Mirsad Dorić, Ajna Hukić, Mirsad Babić, Ivana Tomić,
More informationT he epidermal growth factor receptor (EGFR) is a 170 kda
201 GASTRIC CANCER Reduced expression of epidermal growth factor receptor related protein in gastric cancer W S Moon, A S Tarnawski, J Chai, J T Yang, A P N Majumdar... See end of article for authors affiliations...
More informationImmunohistochemical Determination of HER-2/neu Expression in Invasive Breast Carcinoma
Anatomic Pathology / HER-2/NEU IN BREAST CARCINOMA Immunohistochemical Determination of HER-2/neu Expression in Invasive Breast Carcinoma Russell Vang, MD, 1 Linda D. Cooley, MD, 1 Wilbur R. Harrison,
More informationROLE OF TTF-1, CK20, AND CK7 IMMUNOHISTOCHEMISTRY FOR DIAGNOSIS OF PRIMARY
Y.C. Su, Y.C. Hsu, and C.Y. Chai ROLE OF TTF-1, CK20, AND CK7 IMMUNOHISTOCHEMISTRY FOR DIAGNOSIS OF PRIMARY AND SECONDARY LUNG ADENOCARCINOMA Yue-Chiu Su 1, Yu-Chang Hsu 2, and Chee-Yin Chai 1,3 Departments
More informationExpression and Significance of GRP78 and HER-2 in Colorectal Cancer
Expression and Significance of GRP78 and HER-2 in Colorectal Cancer Qiu-xia Ji 1, Li-li Wang 2, Lin Li 3, Xiaoming Xing 2 1 Department of Pathology, Qingdao University, Qingdao, China 2 Department of Pathology,
More informationWT1, Estrogen Receptor, and Progesterone Receptor as Markers for Breast or Ovarian Primary Sites in Metastatic Adenocarcinoma to Body Fluids
Anatomic Pathology / WT1, ESTROGEN RECEPTOR, AND PROGESTERONE RECEPTOR IN CYTOLOGY OF BODY FLUIDS WT1, Estrogen Receptor, and Progesterone Receptor as Markers for Breast or Ovarian Primary Sites in Metastatic
More informationAn International Journal
ABBR journal.. Vol. 1, No. 1 (2017) Archives of Biological and Biomedical Research An International Journal @ 2017 NSP Natural Sciences Publishing Cor. Expression of C-KIT Tyrosine Kinase Receptor, Epidermal
More information8 years later! Next Generation Sequencing. Pathogenic Findings: HNF1A c.864delinscc, p.g292rfs*25 (NM_ ) (VAF: 59%) HNF1A Loss
8 years later! Next Generation Sequencing Pathogenic Findings: HNF1A c.864delinscc, p.g292rfs*25 (NM_000545.6) (VAF: 59%) HNF1A Loss Interpretation HNF1A c.864delinscc, p.g292rfs*25 (NM_000545.6) This
More informationConcise Reference. HER2 Testing in Breast Cancer. Mary Falzon, Angelica Fasolo, Michael Gandy, Luca Gianni & Stefania Zambelli
Concise Reference Testing in Breast Cancer Mary Falzon, Angelica Fasolo, Michael Gandy, Luca Gianni & Stefania Zambelli Extracted from Handbook of -Targeted Agents in Breast Cancer ublished by Springer
More informationCharacterization and significance of MUC1 and c-myc expression in elderly patients with papillary thyroid carcinoma
Characterization and significance of MUC1 and c-myc expression in elderly patients with papillary thyroid carcinoma Y.-J. Hu 1, X.-Y. Luo 2, Y. Yang 3, C.-Y. Chen 1, Z.-Y. Zhang 4 and X. Guo 1 1 Department
More informationExpression Pattern of Smad Proteins in Diffuse Large B-cell Lymphomas
The Korean Journal of Pathology 2004; 38: 301-5 Expression Pattern of Smad Proteins in Diffuse Large B-cell Lymphomas Department of Pathology, Dankook University College of Medicine, Cheonan, Korea Received
More informationHepatocellular Adenomas: Genetics & Imaging Update 2017
No financial disclosures Hepatocellular Adenomas: Genetics & Imaging Update 2017 Srinivasa Prasad MD The UT MD Anderson Cancer Center Aims & Objectives To provide a current update on genetics & molecular
More information7/6/2015. Cancer Related Deaths: United States. Management of NSCLC TODAY. Emerging mutations as predictive biomarkers in lung cancer: Overview
Emerging mutations as predictive biomarkers in lung cancer: Overview Kirtee Raparia, MD Assistant Professor of Pathology Cancer Related Deaths: United States Men Lung and bronchus 28% Prostate 10% Colon
More informationSupplementary Online Content
Supplementary Online Content Rimm DL, Han G, Taube JM, et al. A prospective, multi-institutional, pathologistbased assessment of 4 immunohistochemistry assays for PD-L1 expression in non small cell lung
More informationThermo Scientific UltraVision Quanto for Immunohistochemistry The New Generation Micro-Polymer Detection System
Thermo Scientific for Immunohistochemistry The New Generation Micro-Polymer Detection System highest sensitivity sharp crisp clear shorter incubation times UltraVision Quanto the new Micro-Polymer System
More informationVascular Endothelial Growth Factor Expression in Oral Epithelial Dysplasia and Oral Squamous Cell Carcinoma
OMPJ Vascular Endothelial Growth Factor Expression in Oral Epithelial Dysplasia 10.5005/jp-journals-10037-1003 and Oral Squamous Cell Carcinoma ORIGINAL RESEARCH Vascular Endothelial Growth Factor Expression
More informationHER-2/neu Marker Examination using Immunohistochemical Method in Patients Suffering from Gastric Adenocarcinoma
IJMCM Autumn 203, Vol 2, No 4 Original Article HER-2/neu Marker Examination using Immunohistochemical Method in Patients Suffering from Gastric Adenocarcinoma Kourosh Movagharnejad, Majid Sharbatdaran,
More informationTHE STUDY ON RELATIONSHIP BETWEEN CIGARETTE SMOKING AND THE p53 PROTEIN AND P21 PROTEIN EXPRESSION IN NON-SMALL LUNG CANCER
( Thmese Journal of ('ancer Research 8(3): 187-19L 1996. THE STUDY ON RELATIONSHIP BETWEEN CIGARETTE SMOKING AND THE p53 PROTEIN AND P21 PROTEIN EXPRESSION IN NON-SMALL LUNG CANCER ZhouBaosen )~j'#:~ lleanguang
More informationFunctional assay for HER-2/neu demonstrates active signalling in a minority of HER-2/neu-overexpressing invasive human breast tumours
Britsh Journal of Cancer (1996) 74, 802-806 $0 (g 1996 Stockton Press All rights reserved 0007-0920/96 $12.00 Functional assay for HER-2/neu demonstrates active signalling in a minority of HER-2/neu-overepressing
More informationImmunohistochemical Expression of Hormone Receptors and The Histological Characteristics of Biochemically Hormone Receptor Negative Breast Cancers
Breast Cancer Vol. 14 No. 1 January 2007 Original Article Immunohistochemical Expression of Hormone Receptors and The Histological Characteristics of Biochemically Hormone Receptor Negative Breast Cancers
More informationMegakaryoblastic Leukemia in a Dog A. Hillström 1, H. Tvedten 1, M. Kiupel 2.
Megakaryoblastic Leukemia in a Dog A. Hillström 1, H. Tvedten 1, M. Kiupel 2. 1 University Animal Hospital, Swedish University of Agricultural Sciences and Strömsholm Referral Animal Hospital, Sweden 2
More informationClinical significance of CD44 expression in children with hepatoblastoma
Clinical significance of CD44 expression in children with hepatoblastoma H.-Y. Cai 1 *, B. Yu 1 *, Z.-C. Feng 2, X. Qi 1 and X.-J. Wei 1 1 Department of General Surgery, General Hospital of Beijing Military
More informationEstrogen receptor (ER)
Material The slide to be stained for ER comprised: Assessment Run B26 2018 Estrogen receptor (ER) No. Tissue ER-positivity* ER-intensity* 1. Uterine cervix 80-90% Moderate to strong 2. Tonsil 1-5% Weak
More informationTUMOR M ARKERS MARKERS
TUMOR MARKERS M.Shekarabi IUMS Definition Many cancers are associated with the abnormal production of some molecules l which h can be measured in plasma. These molecules are known as tumor markers. A good
More informationCoordinate Expression of Cytokeratins 7 and 20 in Prostate Adenocarcinoma and Bladder Urothelial Carcinoma
Anatomic Pathology / CYTOKERATINS 7 AND 20 IN PROSTATE AND BLADDER CARCINOMAS Coordinate Expression of Cytokeratins 7 and 20 in Prostate Adenocarcinoma and Bladder Urothelial Carcinoma Nader H. Bassily,
More informationCorrelation between expression and significance of δ-catenin, CD31, and VEGF of non-small cell lung cancer
Correlation between expression and significance of δ-catenin, CD31, and VEGF of non-small cell lung cancer X.L. Liu 1, L.D. Liu 2, S.G. Zhang 1, S.D. Dai 3, W.Y. Li 1 and L. Zhang 1 1 Thoracic Surgery,
More informationVascular endothelial growth factor (VEGF)-C, VEGF-D, VEGFR-3 and D2-40 expressions in primary breast cancer: Association with lymph node metastasis
Original papers Vascular endothelial growth factor (VEGF)-C, VEGF-D, VEGFR-3 and D2-40 expressions in primary breast cancer: Association with lymph node metastasis Aydan Eroğlu 1, A F, Cevriye Ersöz 2,
More informationCitation Acta Medica Nagasakiensia. 1992, 37
NAOSITE: Nagasaki University's Ac Title Author(s) Immunohistochemical Study on Blood Antigens in Primary Breast Carcinom Tomita, Masao; Nakagoe, Toru; Kawah Tagawa, Yutaka Citation Acta Medica Nagasakiensia.
More informationResults you can trust
PRODUCT I NF OR MAT ION pharmdx Results you can trust The first and only FDA-approved PD-L1 test to assess the magnitude of treatment effect on progression-free survival in melanoma patients from OPDIVO
More informationDeepa Taggarshe MD MRCS M Phil, Catherine Lobocki MS, Alasdair McKendrick MD FACS, Vijay K Mittal MD FACS
Clinicopathological significance of expression of Estrogen Receptor-Beta (ERβ), Progesterone Receptor(PR) and Vascular Endothelial Growth Factor- A (VEGF) in colorectal cancer. Deepa Taggarshe MD MRCS
More informationTumor responses (patients responding/ patients treated)
Table 1. ACT clinical trial tumor responses and toxicities. a Target antigen Cancer(s) Receptor type Tumor responses (patients responding/ patients treated) Immune-mediated toxicities (patients experiencing
More informationProduct Datasheet. CD133 Antibody NB Unit Size: 0.1 mg
Product Datasheet CD133 Antibody NB120-16518 Unit Size: 0.1 mg Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles. Publications: 8 Protocols, Publications, Related Products,
More informationLiver Specialty Evening Conference. Matthew M. Yeh, MD, PhD Professor of Pathology Adjunct Professor of Medicine University of Washington, Seattle
Liver Specialty Evening Conference Matthew M. Yeh, MD, PhD Professor of Pathology Adjunct Professor of Medicine University of Washington, Seattle Case History A 65 year-old man presents with abdominal
More informationCyclooxygenase-2 Expression Determines Neoangiogenesis in Gallbladder Carcinomas
& Cyclooxygenase-2 Expression Determines Neoangiogenesis in Gallbladder Carcinomas Mateja Legan¹*, Boštjan Luzar², Vera Ferlan-Marolt², Andrej Cör¹ 1. Institute of Histology and Embryology, Faculty of
More informationAssessment performed on Tuesday, July 29, 2014, at Lions Gate Hospital, North Vancouver
Assessors report for ciqc Run 37: BRAF V600E (April 2014) Assessors: B Gilks, R Wolber, K Ung, P Tavassoli, J Garratt and J Won (recorder) Assessment performed on Tuesday, July 29, 2014, at Lions Gate
More informationExpression and clinical significance of ADAM17 protein in esophageal squamous cell carcinoma
Expression and clinical significance of ADAM17 protein in esophageal squamous cell carcinoma H.B. Liu, Y. Zhu, Q.C. Yang, Y. Shen, X.J. Zhang and H. Chen Department of Pathology First People s Hospital
More informationOriginal Article. Evaluation of Expression of EGFR, HER-2 and COX-2 in Colorectal Cancer. Behrang Kazeminegad, Abbas Mirafsharieh, Freidoon Solhjoo
Iranian Journal of Pathology (2012) 7 (3), 139-144 139 Original Article Evaluation of Expression of EGFR, HER-2 and COX-2 in Colorectal Cancer Behrang Kazeminegad, Abbas Mirafsharieh, Freidoon Solhjoo
More informationImmunohistochemical Evaluation of Necrotic Malignant Melanomas
Anatomic Pathology / EVALUATION OF NECROTIC MALIGNANT MELANOMAS Immunohistochemical Evaluation of Necrotic Malignant Melanomas Daisuke Nonaka, MD, Jordan Laser, MD, Rachel Tucker, HTL(ASCP), and Jonathan
More informationAnnals of Oncology, Volume 26, Issue suppl_9, 1 December 2015, Pages ix3, Published: 19 December 2015
We Article use Navigation cookies to enhance your experience on our website. By clicking 'continue' or by continuing to use our website, you are agreeing to our use of cookies. You can change your cookie
More informationOriginal Article CREPT expression correlates with esophageal squamous cell carcinoma histological grade and clinical outcome
Int J Clin Exp Pathol 2017;10(2):2030-2035 www.ijcep.com /ISSN:1936-2625/IJCEP0009456 Original Article CREPT expression correlates with esophageal squamous cell carcinoma histological grade and clinical
More informationCANCER. Clinical Validation of Breast Cancer Predictive Markers
Clinical Validation of Breast Cancer Predictive Markers David Hicks, MD Loralee McMahon, MS, HTL(ASCP) CANCER The human body is composed of billions of highly regulated cells Cancer cells no longer respond
More informationPD-L1 Analyte Control DR
Quality in Control PD-L1 Analyte Control DR PD-L1_PI_v2 Product Codes: HCL019, HCL020 and HCL021 Contents PD-L1 Analyte Control DR 2 What is PD-L1? 3 The Role of PD-L1 in Cancer 3 PD-L1 Assessment 4 PD-L1
More informationAssessment performed on Friday, September 18, 2015, at Vancouver General Hospital
Assessors report for ciqc Run 49: ATRX (June 2015) Assessors: S Yip and J Won (recorder) Assessment performed on Friday, September 18, 2015, at Vancouver General Hospital Background The combined application
More informationResearch Article Altered Expression of Cellular Bcl-2 in the Progression of Hamster Cholangiocarcinogenesis
The Scientific World Journal Volume 2012, Article ID 385840, 6 pages doi:10.1100/2012/385840 The cientificworldjournal Research Article Altered Expression of Cellular Bcl-2 in the Progression of Hamster
More informationc-erbb-2 expression and prognosis of gastric cancer: a meta-analysis
c-erbb-2 expression and prognosis of gastric cancer: a meta-analysis Z.Q. Wang and B.J. Sun Department of Surgery, Affiliated Tongren Hospital, Shanghai Jiaotong University, Shanghai, China Corresponding
More informationImaging of glycolytic metabolism in primary glioblastoma cells with
63 Chapter 5 Imaging of glycolytic metabolism in primary glioblastoma cells with RIMChip 5.1. Introduction Glioblastoma(GBM) is one of the most common brain tumors 1. It is composed of heterogeneous subpopulations
More informationExpression of the Tumour Suppressor Gene p53 in Odontogenic Cysts
Turk J Med Sci 33 (2003) 243-247 TÜB TAK CLINICAL INVESTIGATIONS Expression of the Tumour Suppressor Gene p53 in Odontogenic Cysts Ayla ÖZVEREN 1, Can TUSKAN 3, Mehmet YALTIRIK 3, Belir ATALAY 3, Gülçin
More informationIntrahepatic Sarcomatoid Cholangiocarcinoma with Portal Vein Thrombosis: A Case Report 1
Intrahepatic Sarcomatoid Cholangiocarcinoma with Portal Vein Thrombosis: A Case Report 1 Jae-Hoon Lim, M.D., Jin Woong Kim, M.D., Suk Hee Heo, M.D., Yong Yeon Jeong, M.D., Heoung Keun Kang, M.D. A 53-year-old
More informationExosomal Del 1 as a potent diagnostic marker for breast cancer : A prospective cohort study
GBCC 2017: ABS-0017 Exosomal Del 1 as a potent diagnostic marker for breast cancer : A prospective cohort study Soo Jung Lee 1, Jeeyeon Lee 2, Jin Hyang Jung 2, Ho Yong Park 2, Chan Hyeong Lee 3, Pyong
More informationNeoplasia 2018 lecture 11. Dr H Awad FRCPath
Neoplasia 2018 lecture 11 Dr H Awad FRCPath Clinical aspects of neoplasia Tumors affect patients by: 1. their location 2. hormonal secretions 3. paraneoplastic syndromes 4. cachexia Tumor location Even
More informationSenior of Histopathology Department at Khartoum, Radiation and Isotopes Center
EUROPEAN ACADEMIC RESEARCH Vol. IV, Issue 2/ May 2016 ISSN 2286-4822 www.euacademic.org Impact Factor: 3.4546 (UIF) DRJI Value: 5.9 (B+) Immune Histochemical Evaluation of AMACR (P504S) in Prostatic Adenocarcinoma
More informationPhospho-PRAS40 Thr246 predicts trastuzumab response in patients with HER2-positive metastatic breast cancer
ONCOLOGY LETTERS 9: 785-789, 2015 Phospho-PRAS40 Thr246 predicts trastuzumab response in patients with HER2-positive metastatic breast cancer KAI YUAN, HONGYAN WU, YULONG WANG, HONGQIANG CHEN, MINGWEN
More informationCyclin-D1 protooncogen expression in prostate cancer
Turkish Journal of Cancer Vol.30 / No. 1/2000 Cyclin-D1 protooncogen expression in prostate cancer EMİN ÖZBEK 1, BÜLENT MIZRAK 2, MUSTAFA ÖZBEK 3, SÜLEYMAN BÜYÜKBERBER 4, MÜRSEL DAVARCI 1 Departments of
More information(A) PCR primers (arrows) designed to distinguish wild type (P1+P2), targeted (P1+P2) and excised (P1+P3)14-
1 Supplemental Figure Legends Figure S1. Mammary tumors of ErbB2 KI mice with 14-3-3σ ablation have elevated ErbB2 transcript levels and cell proliferation (A) PCR primers (arrows) designed to distinguish
More informationBrief Formalin Fixation and Rapid Tissue Processing Do Not Affect the Sensitivity of ER Immunohistochemistry of Breast Core Biopsies
Brief Formalin Fixation and Rapid Tissue Processing Do Not Affect the Sensitivity of ER Immunohistochemistry of Breast Core Biopsies Victoria Sujoy, MD, Mehrdad Nadji, MD, and Azorides R. Morales, MD From
More informationFOR REVIEW. BMB Reports - Manuscript Submission. Manuscript Draft. Manuscript Number: BMB
BMB Reports - Manuscript Submission Manuscript Draft Manuscript Number: BMB-18-095 Title: Insulin Receptor Substrate 2:A Bridge between Hippo and AKT Pathways Article Type: Perspective (Invited Only) Keywords:
More informationHigher expression of deoxyuridine triphosphatase (dutpase) may predict the metastasis potential of colorectal cancer
1 Department of Diagnostic Pathology, Kurume University Hospital, Kurume, Japan; 2 Department of Surgery, Kurume University School of Medicine, Kurume, Japan; 3 Biostatistics Center, Kurume University,
More informationHypoxia inducible factor-1 alpha and carbonic anhydrase IX overexpression are associated with poor survival in breast cancer patients
Journal of BUON 17: 663-668, 2012 2012 Zerbinis Medical Publications. Printed in Greece ORIGINAL ARTICLE Hypoxia inducible factor-1 alpha and carbonic anhydrase IX overexpression are associated with poor
More informationDetection and Characterization of Hepatocellular Carcinoma by Imaging
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2005;3:S136 S140 Detection and Characterization of Hepatocellular Carcinoma by Imaging OSAMU MATSUI Department of Imaging Diagnosis and Interventional Radiology,
More information1. Basic principles 2. 6 hallmark features 3. Abnormal cell proliferation: mechanisms 4. Carcinogens: examples. Major Principles:
Carcinogenesis 1. Basic principles 2. 6 hallmark features 3. Abnormal cell proliferation: mechanisms 4. Carcinogens: examples Carcinogenesis Major Principles: 1. Nonlethal genetic damage is central to
More informationThyroid transcription factor-1 (TTF1) Assessment run
Thyroid transcription factor- (TTF) Assessment run 39 203 The slide to be stained for TTF comprised:. Thyroid gland, 2. Liver, 3. Normal lung, 4. Lung adenocarcinoma 5. Colon adenocarcinoma, 6 & 7. Lung
More informationDiscovery and Optimization of Inhibitors of STAT3 Activation for the Treatment of Squamous Cell Carcinoma of the Head and Neck
Discovery and ptimization of Inhibitors of STAT3 Activation for the Treatment of Squamous Cell Carcinoma of the Head and Neck Feng Zhang Wipf Group Research Topic Seminar 02-09-2013 1 Feng Zhang @ Wipf
More informationRESEARCH ARTICLE. Crosstalk between EGFR and p53 in Hepatocellular Carcinoma
RESEARCH ARTICLE Crosstalk between EGFR and p53 in Hepatocellular Carcinoma Andreea Cioca 1 *, Anca Cimpean 2, Raluca Ceausu 2, Ana-Maria Fit 1, Teodor Zaharie 3, Nadim Al-Hajjar 4, Vlad Puia 4, Marius
More informationSupplement 8: Candidate age-related genes and pathways
Supplement 8: Candidate age-related genes and pathways Function Untreated cohort (cohort 1) Treated cohort (cohort 2) Genes Gene sets Effect of age Effect of age FDR of 2 nd Effect of age adjusted Effect
More informationDifferential diagnosis of malignant epithelial tumours in the liver: an immunohistochemical study on liver biopsy material
508 Al-Muhannadi N, et al., 2011; 10 (4): 508-515 ORIGINAL ARTICLE October-December, Vol. 10 No.4, 2011: 508-515 Differential diagnosis of malignant epithelial tumours in the liver: an immunohistochemical
More information# Best Practices for IHC Detection and Interpretation of ER, PR, and HER2 Protein Overexpression in Breast Cancer
#1034 - Best Practices for IHC Detection and Interpretation of ER, PR, and HER2 Protein Overexpression in Breast Cancer Richard W. Cartun, MS, PhD Andrew Ricci, Jr, MD Department of Pathology Hartford
More informationCorrelation of Vascular Endothelial Growth Factor Expression and Neovascularization with Colorectal Carcinoma: A Pilot Study
Research Article imedpub Journals http://www.imedpub.com Journal of Adenocarcinoma Vol. 1 No. 1:5 DOI: 10.21767/2572-309X.10005 Correlation of Vascular Endothelial Growth Factor Expression and Neovascularization
More informationProstate Immunohistochemistry. Literature Interpretation: Caveats. Must be aware of staining pattern of antibody in the relevant tissue
IHC Interpretation: General Principles (1) Prostate Immunohistochemistry Murali Varma Cardiff, UK wptmv@cf.ac.uk Sarajevo Nov 2013 Must be aware of staining pattern of antibody in the relevant tissue Nuclear/cytoplasmic/membranous
More informationExpression of Antioxidant Enzymes (Catalase, Superoxide Dismutase, and Glutathione Peroxidase) in Human Bladder Cancer
Expression of Antioxidant Enzymes (Catalase, Superoxide Dismutase, and Glutathione Peroxidase) in Human Bladder Cancer Seung Hyun Jeon, Jae-Hoon Park 1, Sung-Goo Chang From the Departments of Urology and
More informationEstrogen receptor (ER)
Material The slide to be stained for ER comprised: Assessment B25 208 Estrogen receptor (ER) No. Tissue ER-positivity* ER-intensity*. Uterine cervix 80-90% Moderate to strong 2. Tonsil < 2-5% Weak to strong
More informationGenetics of Cancer Lecture 32 Cancer II. Prof. Bevin Engelward, MIT Biological Engineering Department
Genetics of Cancer Lecture 32 Cancer II rof. Bevin Engelward, MIT Biological Engineering Department Why Cancer Matters New Cancer Cases in 1997 Cancer Deaths in 1997 Genetics of Cancer: Today: What types
More informationnumber Done by Corrected by Doctor Maha Shomaf
number 19 Done by Waseem Abo-Obeida Corrected by Abdullah Zreiqat Doctor Maha Shomaf Carcinogenesis: the molecular basis of cancer. Non-lethal genetic damage lies at the heart of carcinogenesis and leads
More informationThe Angiopoietin Axis in Cancer
Ang2 Ang1 The Angiopoietin Axis in Cancer Tie2 An Overview: The Angiopoietin Axis Plays an Essential Role in the Regulation of Tumor Angiogenesis Growth of a tumor beyond a limiting size is dependent upon
More informationDr. dr. Primariadewi R, SpPA(K)
Curriculum Vitae Dr. dr. Primariadewi R, SpPA(K) Education : Medical Doctor from UKRIDA Doctoral Degree from Faculty of Medicine University of Indonesia Pathologist Specialist and Consultant from Faculty
More informationAtypical Well differentiated Hepatocellular Neoplasms Cruising through the maze of criteria, terminology and risk assessment
2016 Hans Popper Companion Meeting Atypical Well differentiated Hepatocellular Neoplasms Cruising through the maze of criteria, terminology and risk assessment Disclosure Dr. Kakar has nothing to Disclose
More informationAnti-DC-SIGN/CD209 murine monoclonal antibodies
Anti-DC-SIGN/CD209 murine monoclonal antibodies DC-SIGN (DC Specific, ICAM-3 Grabbing, Nonintegrin) / CD209 and L-SIGN (liver/lymph node-specific ICAM-3-grabbing nonintegrin CD299/ DC-SIGNR (DC-SIGN-related
More informationTissue-Specific Cadherin CDH17 Is a Useful Marker of Gastrointestinal Adenocarcinomas With Higher Sensitivity Than CDX2
Anatomic Pathology / CDH17 in Gastrointestinal Carcinomas Tissue-Specific Cadherin CDH17 Is a Useful Marker of Gastrointestinal Adenocarcinomas With Higher Sensitivity Than CDX2 Nicole C. Panarelli, MD,
More informationNew Approaches in Brain Tumor Treatment. Virginia Stark-Vance, M.D.
New Approaches in Brain Tumor Treatment Virginia Stark-Vance, M.D. The Primary Brain Tumors es for PicturesMCD for 004.JPG 00 Meningioma 30% Glioblastoma 20% Astrocytoma 10% Nerve sheath 8% Pituitary 6%
More informationKey words: superoxide dismutase, colo-rectal cancer, immunohistochemistry
Key words: superoxide dismutase, colo-rectal cancer, immunohistochemistry Table I Immunohistochemical stainins of SOD in the colorectal cancer Histological diagnosis normal mucosa # cancer well diff. moderate
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: van Seters M, van Beurden M, ten Kate FJW, et al. Treatment
More information